ABSTRACT
The antiviral properties of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir [CDV]) were first reported in 1986 (De Clercq et al., 1986). Nine years after it was first described as an antiviral agent active against cytomegalovirus (CMV) and other DNA viruses, the intravenous form of CDV was approved (in 1996) for the systemic treatment of CMV retinitis in patients with HIV infection and AIDS. It was marketed by Gilead Sciences under the trade name of Vistide, and in June 2010 the patent expired. In March 2013, InnoPharma (which was acquired by Pfizer in July 2014) launched the generic equivalent of Vistide). The generic formulation of CDV developed by InnoPharma was marketed in the USA by Mylan. Also, Emcure Pharmaceuticals manufactures generic CDV injection for Heritage Pharmaceuticals in India.
